Finland· FI-REL-REL47802
CINQAERO
A reslizumab product containing reslizumab, registered in Finland by Teva B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Reslizumab is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DX08 (reslizumab), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Reslizumab · ATC R03DX08
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Fimea (Finland)- Active substance
- Reslizumab
- Manufacturer
- Teva B.V.
- Country
- Finland (FI)
- ATC code
- R03DX08
- ATC class
- Reslizumab
- Defined daily dose
- 7.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reslizumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaCINQAEROTeva B.V., Haarlem
- BelgiumCinqaero 10 mg/mlTeva
- IrelandCINQAERO 10 mg/mL concentrate for solution for infusionTeva B.V.
- IcelandCinqaeroTeva B.V.*
- PolandCinqaeroTeva B.V.
- SwedenCINQAERO 10 mg/ml Koncentrat till infusionsvätska, lösningTeva B.V.
- United StatesCINQAIRTeva Respiratory, LLC
- SwitzerlandCinqaero 100 mg/10 mL, Konzentrat zur Herstellung einer InfusionslösungTeva Pharma AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Cinqaero
- Iceland · Cinqaero
- Liechtenstein · Cinqaero
- Norway · Cinqaero
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/2adc5553-e1ed-4a9a-9a52-322d8f79babe GET /v1/drugs/2adc5553-e1ed-4a9a-9a52-322d8f79babe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "7.1",
"form": "infuusiokonsentraatti, liuosta varten",
"route": "Laskimoon",
"ddd_unit": "mg",
"strength": "10 mg/ml",
"atc_label": "reslitsumabi",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/16/1125/001-004",
"fimea_rel_id": "REL47802",
"authorised_at": "2016-08-16"
}See everything about reslizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.